Illumina, a leading name in DNA sequencing and array-based technologies, presented its latest research findings at the American Society of Clinical Oncology (ASCO) Annual Meeting held from May 31st to June 4th, 2024, in Chicago. The presentations highlighted the company’s commitment to advancing genomic testing in cancer care through collaborations and ongoing research initiatives.
Focus on Collaboration and Evidence-Based Solutions
A key theme of Illumina’s presentations was collaboration across various stakeholders in the oncology field. This included partnerships with leading institutions like Labcorp, Sarah Cannon Research Institute (SCRI), and Eurofins. The focus was on generating strong evidence to support the clinical utility and value of comprehensive genomic profiling (CGP) for cancer patients.
Machine Learning for Enhanced Tumor Detection
One of the collaborative efforts involved Illumina and Labcorp. Together, they presented research on a machine learning algorithm for detecting tumor microsatellite instability (MSI) using multiomics biomarkers (Abstract 1554). This approach, trained on data from over 1800 colorectal cancer patients, demonstrated promising results in accurately assessing MSI status.
CGP Takes Center Stage: Demonstrating Advantages Over Single-Gene Testing
Illumina’s commitment to CGP was evident in its collaboration with SCRI. A real-world analysis (Abstract 8640) compared the performance of CGP to single-gene testing (SGT) in selecting guideline-recommended biomarkers for non-small-cell lung cancer (NSCLC). The findings showed a significant advantage for CGP, with 71.7% of patients receiving results for all nine guideline-recommended biomarkers compared to only 1.2% with SGT.
Building on Previous Findings: Impact of SGT on CGP Utilization
This year’s research builds on prior collaborations, including a 2023 study with Labcorp demonstrating that upfront SGT use often leads to CGP test cancellations. This suggests that SGT practices in community oncology settings may not align with best practices and could negatively impact patient access to the benefits of CGP.
Paving the Way for Early Cancer Detection: Illumina’s MRD Assay
Illumina also presented data on its next-generation molecular residual disease (MRD) assay (Abstract 3060). This assay, currently under development, is designed to offer faster turnaround times, lower sample requirements, and improved sensitivity and specificity compared to existing options.
Looking Ahead: Personalized Cancer Care Through Precision Oncology
Illumina’s participation at ASCO 2024 underscores its dedication to advancing precision oncology solutions. By collaborating with key players in the field and conducting impactful research, Illumina aims to unlock the full potential of genomic testing for improved patient outcomes.
